COMy 2021 - 7th World Congress on Controversies in Multiple Myeloma (Virtual Meeting)
May 07 - May 09, 2021 | ParisFrance
LARVOL is not affiliated with 7th World Congress on Controversies in Multiple Myeloma (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 23 abstracts linked to Trials
[VIRTUAL] SECONDARY QUALITY-OF-LIFE DOMAINS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH THE BCMA-DIRECTED CAR T CELL THERAPY IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121): RESULTS FROM THE KARMMA CLINICAL TRIAL
[VIRTUAL] CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
[VIRTUAL] DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS INELIGIBLE FOR TRANSPLANTATION: FRAILTY SUBGROUP ANALYSIS OF ALCYONE
[VIRTUAL] DARATUMUMAB PLUS LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF GRIFFIN AFTER 12 MONTHS OF MAINTENANCE THERAPY
[VIRTUAL] PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), BCMA-DIRECTED CAR-T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
[VIRTUAL] REAL-WORLD EFFICACY AND TOLERABILITY OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): INTERIM ANALYSIS OF THE REMIX STUDY
[VIRTUAL] TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) X CD3 BISPECIFIC ANTIBODY, IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM AN ONGOING PHASE 1 STUDY
[VIRTUAL] TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS
[VIRTUAL] UPDATED ANALYSIS OF DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TIE-NDMM): THE PHASE 3 MAIA STUDY
[VIRTUAL] DARATUMUMAB SC + SOC IN MM ACROSS LINES OF THERAPY IN PHASE-2 PLEIADES: INITIAL RESULTS FOR DARATUMUMAB SC + CARFILZOMIB/DEXAMETHASONE AND UPDATED RESULTS FOR DARATUMUMAB SC + BORTEZOMIB/MELPHALAN/PREDNISONE OR LENALIDOMIDE/DEXAMETHASONE
[VIRTUAL] DREAMM-2 (NCT03525678): SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF) EFFECTS ON PATIENT-REPORTED OUTCOME (PRO) MEASURES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
[VIRTUAL] CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN THE PHASE 1B/2 CARTITUDE-1 STUDY
[VIRTUAL] HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
[VIRTUAL] HORIZON (OP-106): MELFLUFEN PLUS DEXAMETHASONE IN 55 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH EXTRAMEDULLARY DISEASE (EMD)—SUBGROUP ANALYSIS
[VIRTUAL] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA HIGH-RISK SUBGROUP ANALYSES